PHILADELPHIA, March 7, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc.(NASDAQ MKT: GNMX) today announced that it has expanded its collaboration with Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) with the signing of an option agreement for an early stage monoclonal antibody program ("program") in an ultra-orphan pediatric indication.
Aevi Genomic Medicine and Kyowa Hakko Kirin have developed a collaboration framework to advance preclinical programs into the clinic, leveraging Aevi Genomic Medicine's expertise in rare and orphan pediatric diseases, and its ongoing collaboration with Children's Hospital of Philadelphia ("CHOP") and the biobank at the Center for Applied Genomics at CHOP. This new program will focus on an undisclosed, first-in-class monoclonal antibody targeting a specific cell surface marker implicated in an auto-immune ultra-orphan disease that primarily affects children.
"We are very excited to be deepening our partnership with Kyowa Hakko Kirin to identify and validate new potential targets in human disease," said Garry Neil, Chief Scientific Officer of Aevi Genomic Medicine. "We believe that this new program will demonstrate an ability to shorten development of novel medicines through a rigorous precision medicine methodology that pairs targeted KHK discoveries with the right patients in rare and orphan diseases by utilizing the comprehensive collection of rare and orphan specimens in the CHOP Biobank."
Financial and other terms of the deal were not disclosed.
About Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP).
About Kyowa Hakko Kirin
Kyowa Hakko Kirin Co., Ltd. is a research-based life sciences company, with special strengths in biotechnologies. In the core therapeutic areas of oncology, nephrology and immunology / allergy, Kyowa Hakko Kirin leverages leading-edge biotechnologies centered on antibody technologies, to continually discover innovative new drugs and to develop and market those drugs world-wide. In this way, the company is working to realise its vision of becoming a Japan-based global specialty pharmaceutical company that contributes to the health and wellbeing of people around the world. You can learn more about the business at: www.kyowa-kirin.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.
Aevi Genomic Medicine, Inc.
View original content:http://www.prnewswire.com/news-releases/aevi-genomic-medicine-expands-collaboration-with-kyowa-hakko-kirin-300609506.html
SOURCE Aevi Genomic Medicine, Inc.